CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active therapies and devices to treat serious illnesses, today announced new data from Phase 1 and 2 clinical trials of Vascugel®, a novel allogeneic cell therapy product that may restore natural repair and regeneration pathways in the vasculature. Data from these trials indicate that Vascugel® has an excellent safety profile in patients with end-stage renal disease (ESRD) that need permanent arteriovenous (AV) access for dialysis, with fewer thrombotic events, local wound infections, early complications and interventions compared to placebo. The data were presented during a poster session at the American Society of Nephrology Annual Meeting in Philadelphia on November 6, 2008.
